Cargando…
Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms
BACKGROUND: Anti-interleukin (IL)-23 agents are widely used for autoimmune disease treatment; however, the safety and risks of specific symptoms have not been systematically assessed. OBJECTIVES: The aim of this study was to summarize the characteristics and mechanisms of occurrence of five immunolo...
Autores principales: | Ru, Yi, Ding, Xiaojie, Luo, Ying, Li, Hongjin, Sun, Xiaoying, Zhou, Mi, Zhou, Yaqiong, Kuai, Le, Xing, Meng, Liu, Liu, Luo, Yue, Song, Jiankun, Chen, Jiale, Li, Bin, Li, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226270/ https://www.ncbi.nlm.nih.gov/pubmed/34177909 http://dx.doi.org/10.3389/fimmu.2021.670398 |
Ejemplares similares
-
Adverse Events Associated With Treatment of Tripterygium wilfordii Hook F: A Quantitative Evidence Synthesis
por: Ru, Yi, et al.
Publicado: (2019) -
Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review
por: Wang, Jiao, et al.
Publicado: (2023) -
Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials
por: Luo, Yue, et al.
Publicado: (2021) -
Establishment of Mouse Models of Psoriasis with Blood Stasis Syndrome Complicated with Glucose and Lipid Metabolism Disorders
por: Luo, Ying, et al.
Publicado: (2019) -
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
por: Sun, Xiaoying, et al.
Publicado: (2019)